Gene signatures in U-BIOPRED severe asthma for molecular phenotyping and precision medicine: time for clinical use.

Kermani, N; Versi, A; Gay, A; Vlasma, J; Jayalatha, AKS; Koppelman, GH; Nawijn, M; Faiz, A; van den Berge, M; Adcock, IM; Chung, KF

Gene signatures in U-BIOPRED severe asthma for molecular phenotyping and precision medicine: time for clinical use.

Kermani, N Versi, A Gay, A Vlasma, J Jayalatha, AKS Koppelman, GH Nawijn, M Faiz, A

van den Berge, M Adcock, IM Chung, KF

Permalink

Publisher:: TAYLOR & FRANCIS LTD
Publication Type:: Journal Article
Citation:: Expert Rev Respir Med, 2023, 17, (11), pp. 965-971
Issue Date:: 2023

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted versionAdobe PDF (1.52 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Kermani, N
dc.contributor.author	Versi, A
dc.contributor.author	Gay, A
dc.contributor.author	Vlasma, J
dc.contributor.author	Jayalatha, AKS
dc.contributor.author	Koppelman, GH
dc.contributor.author	Nawijn, M
dc.contributor.author	Faiz, A https://orcid.org/0000-0003-1740-3538
dc.contributor.author	van den Berge, M
dc.contributor.author	Adcock, IM
dc.contributor.author	Chung, KF
dc.date.accessioned	2024-01-16T06:17:40Z
dc.date.available	2024-01-16T06:17:40Z
dc.date.issued	2023
dc.identifier.citation	Expert Rev Respir Med, 2023, 17, (11), pp. 965-971
dc.identifier.issn	1747-6348
dc.identifier.issn	1747-6356
dc.identifier.uri	http://hdl.handle.net/10453/174605
dc.description.abstract	INTRODUCTION: The use and generation of gene signatures have been established as a method to define molecular endotypes in complex diseases such as severe asthma. Bioinformatic approaches have now been applied to large omics datasets to define the various co-existing inflammatory and cellular functional pathways driving or characterizing a particular molecular endotype. AREAS COVERED: Molecular phenotypes and endotypes of Type 2 inflammatory pathways and also of non-Type 2 inflammatory pathways, such as IL-6 trans-signaling, IL-17 activation, and IL-22 activation, have been defined in the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes dataset. There has also been the identification of the role of mast cell activation and of macrophage dysfunction in various phenotypes of severe asthma. EXPERT OPINION: Phenotyping on the basis of clinical treatable traits is not sufficient for understanding of mechanisms driving the disease in severe asthma. It is time to consider whether certain patients with severe asthma, such as those non-responsive to current therapies, including Type 2 biologics, would be better served using an approach of molecular endotyping using gene signatures for management purposes rather than the current sole reliance on blood eosinophil counts or exhaled nitric oxide measurements.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	TAYLOR & FRANCIS LTD
dc.relation.ispartof	Expert Rev Respir Med
dc.relation.isbasedon	10.1080/17476348.2023.2278606
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1117 Public Health and Health Services
dc.subject.classification	Respiratory System
dc.subject.classification	3201 Cardiovascular medicine and haematology
dc.subject.mesh	Humans
dc.subject.mesh	Precision Medicine
dc.subject.mesh	Asthma
dc.subject.mesh	Biomarkers
dc.subject.mesh	Phenotype
dc.subject.mesh	Eosinophils
dc.subject.mesh	Eosinophils
dc.subject.mesh	Humans
dc.subject.mesh	Asthma
dc.subject.mesh	Phenotype
dc.subject.mesh	Biomarkers
dc.subject.mesh	Precision Medicine
dc.title	Gene signatures in U-BIOPRED severe asthma for molecular phenotyping and precision medicine: time for clinical use.
dc.type	Journal Article
utslib.citation.volume	17
utslib.location.activity	England
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
pubs.organisational-group	/University of Technology Sydney/Strength - CFI - Centre for Inflammation
utslib.copyright.status	open_access	*
dc.date.updated	2024-01-16T06:17:38Z
pubs.issue	11
pubs.publication-status	Published
pubs.volume	17
utslib.citation.issue	11

Abstract:

INTRODUCTION: The use and generation of gene signatures have been established as a method to define molecular endotypes in complex diseases such as severe asthma. Bioinformatic approaches have now been applied to large omics datasets to define the various co-existing inflammatory and cellular functional pathways driving or characterizing a particular molecular endotype. AREAS COVERED: Molecular phenotypes and endotypes of Type 2 inflammatory pathways and also of non-Type 2 inflammatory pathways, such as IL-6 trans-signaling, IL-17 activation, and IL-22 activation, have been defined in the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes dataset. There has also been the identification of the role of mast cell activation and of macrophage dysfunction in various phenotypes of severe asthma. EXPERT OPINION: Phenotyping on the basis of clinical treatable traits is not sufficient for understanding of mechanisms driving the disease in severe asthma. It is time to consider whether certain patients with severe asthma, such as those non-responsive to current therapies, including Type 2 biologics, would be better served using an approach of molecular endotyping using gene signatures for management purposes rather than the current sole reliance on blood eosinophil counts or exhaled nitric oxide measurements.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/174605